

section 605(b) of the RFA, the Commission proposes to certify that the removal of regulations proposed here will not have a significant economic impact on a substantial number of small entities.

#### V. Information Collection Statement

The Office of Management and Budget's (OMB) regulations require that OMB approve certain information collection requirements imposed by agency rules.<sup>13</sup> However, this proposed rule contains no information reporting requirements, and therefore is not subject to OMB approval.

#### VI. Comment Procedures

The Commission invites interested persons to submit comments, data, views and other information concerning matters set out in this notice.

To facilitate the Commission's review of the comments, commenters are requested to provide an executive summary of their position on the issues raised in the notice. Commenters are requested to identify each specific issue that their discussion addresses and to use appropriate headings. Additional issues the commenters wish to raise should be identified separately. The commenters should double space their comments.

Comments may be filed on paper or electronically via the Internet and must be received by the Commission within 45 days after publication in the **Federal Register**. Those filing electronically do not need to make a paper filing. For paper filings, the original and 14 copies of such comments should be submitted to the Office of the Secretary, Federal Energy Regulatory Commission, 888 First Street, NE, Washington DC 20426 and should refer to Docket No. RM01-6-000.

Comments filed via the Internet must be prepared in WordPerfect, MS Word, Portable Document Format, or ASCII format. To file the document, access the Commission's website at [www.ferc.gov](http://www.ferc.gov) and click on "e-Filing," and then follow the instructions for each screen. First time users will have to establish a user name and password. The Commission will send an automatic acknowledgment to the sender's E-Mail address upon receipt of comments.

User assistance for electronic filing is available at 202-208-0258 or by E-Mail to [efiling@ferc.gov](mailto:efiling@ferc.gov). Comments should not be submitted to the E-Mail address. All comments will be placed in the

Commission's public files and will be available for inspection in the Commission's Public Reference Room at 888 First Street, NE, Washington D.C. 20426, during regular business hours. Additionally, all comments may be viewed, printed, or downloaded remotely via the Internet through FERC's Homepage using the RIMS link.

User assistance for RIMS is available at 202-208-2222, or by E-mail to [RimsMaster@ferc.gov](mailto:RimsMaster@ferc.gov).

#### VII. Document Availability

In addition to publishing the full text of this document in the **Federal Register**, the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the Internet through FERC's Home Page (<http://www.ferc.gov>) and in FERC's Public Reference Room during normal business hours (8:30 a.m. to 5 p.m. Eastern time) at 888 First Street, NE, Room 2A, Washington, DC 20426.

From FERC's Home Page on the Internet, this information is available in both the Commission Issuance Posting System (CIPS) and the Records and Information Management System (RIMS).

—CIPS provides access to the texts of formal documents issued by the Commission since November 14, 1994.

—CIPS can be accessed using the CIPS link or the Energy Information Online icon. The full text of this document is available on CIPS in ASCII and WordPerfect 8.0 format for viewing, printing, and/or downloading.

—RIMS contains images of documents submitted to and issued by the Commission after November 16, 1981. Documents from November 1995 to the present can be viewed and printed from FERC's Home Page using the RIMS link or the Energy Information Online icon. Descriptions of documents back to November 16, 1981, are also available from RIMS-on-the-Web; requests for copies of these and other older documents should be submitted to the Public Reference Room.

User assistance is available for RIMS, CIPS, and the Website during normal business hours from our Help line at (202) 208-2222 (E-Mail to [WebMaster@ferc.gov](mailto:WebMaster@ferc.gov)) or the Public Reference at (202) 208-1371 (E-Mail to [public.referenceroom@ferc.gov](mailto:public.referenceroom@ferc.gov)).

During normal business hours, documents can also be viewed and/or printed in FERC's Public Reference Room, where RIMS, CIPS, and the FERC Website are available. User assistance is also available.

#### List of Subjects in 18 CFR Part 284

Continental shelf, Natural gas, Reporting and recordkeeping requirements, Incorporation by reference.

By direction of the Commission.

Magalie R. Salas,  
Secretary.

In consideration of the foregoing, the Commission proposes to amend part 284, Chapter I, Title 18, Code of Federal Regulations, as follows.

#### PART 284—CERTAIN SALES AND TRANSPORTATION OF NATURAL GAS UNDER THE NATURAL GAS POLICY ACT OF 1978 AND RELATED AUTHORITIES

1. The authority citation for part 284 continues to read as follows:

**Authority:** 15 U.S.C. 717-717w, 3301-3432; 42 U.S.C. 1331-1356.

#### §§ 284.241 and 284.242 (Subpart H) [Removed and reserved]

2. In part 284, remove and reserve subpart H, consisting of §§ 284.241 and 284.242.

[FR Doc. 02-9251 Filed 4-17-02; 8:45 am]

BILLING CODE 6717-01-P

#### SOCIAL SECURITY ADMINISTRATION

##### 20 CFR Part 404

[Regulation No. 4]

RIN 0960-AD67

#### Revised Medical Criteria for Evaluating Hematological Disorders and Malignant Neoplastic Diseases

**AGENCY:** Social Security Administration.

**ACTION:** Proposed rules; reopening of comment period.

**SUMMARY:** We are reopening the comment period for the notice of proposed rulemaking (NPRM) we published in the **Federal Register** (66 FR 59306) on November 27, 2001. Due to the significant issues raised by the commenters, we have decided to provide an additional 60-day public comment period.

**DATES:** The comment date of the NPRM published at 66 FR 59306 is reopened until June 17, 2002.

**ADDRESSES:** You may give us your comments by using our Internet site facility (*i.e.*, Social Security Online) at <http://www.ssa.gov/regulations>; e-mail to [regulations@ssa.gov](mailto:regulations@ssa.gov); telefax to (410) 966-2830; or by letter to the Commissioner of Social Security, P.O. Box 17703, Baltimore, Maryland 21235-

a business which is independently owned and operated and which is not dominant in its field of operations.

<sup>13</sup> 5 CFR Part 1320.

7703. You may also deliver them to the Office of Process and Innovation Management, Social Security Administration, 2109 West Low Rise, 6401 Security Boulevard, Baltimore, Maryland 21235-6401, between 8 a.m. and 4:30 p.m. on regular business days. Comments are posted on our Internet site, or you may inspect them on regular business days by making arrangements with the contact person shown below.

**Electronic Version:** The electronic file of this document is available on the date of publication in the **Federal Register** at [http://www.access.gpo.gov/su\\_docs/aces/aces140.html](http://www.access.gpo.gov/su_docs/aces/aces140.html). It is also available on the Internet site for SSA (i.e., Social Security Online) at <http://www.ssa.gov/regulations/>.

#### FOR FURTHER INFORMATION CONTACT:

Suzanne DiMarino, Social Insurance Specialist, Office of Process and Innovation Management, Social Security Administration, 2109 West Low Rise, 6401 Security Boulevard, Baltimore, Maryland 21235-6401, (410) 966-5995 or TTY (410) 966-5609. For information on eligibility or filing for benefits, call our national toll-free number, 1-800-772-1213 or TTY 1-800-325-0778, or visit our Internet web site, Social Security Online, at [www.ssa.gov](http://www.ssa.gov).

#### SUPPLEMENTARY INFORMATION:

On November 27, 2001, we published "Revised Medical Criteria for Evaluating Hematological Disorders and Malignant Neoplastic Diseases" as an NPRM in the **Federal Register** (66 FR 59306). This NPRM proposed to revise the criteria in the Listing of Impairments (the listings) that we use to evaluate claims involving hematological disorders and malignant neoplastic diseases. In the NPRM, we provided a 60-day comment period that ended January 28, 2002. Most of the comments on the NPRM were received during the end of the comment period. These comments raised significant issues regarding the proposed criteria. In order to allow the public sufficient time to review and comment on these issues, we are providing an additional 60-day comment period. The comments are posted on our Internet site (i.e., Social Security Online) at <http://www.ssa.gov/regulations>. We are also providing a list of the medical and other technical sources we consulted when we developed these proposed rules.

#### References

A list of the sources we consulted when developing the NPRM "Revised Medical Criteria for Evaluating Hematological Disorders and Malignant Neoplastic Diseases" (66 FR 59306) include the following:

Richard Pazdur, ed., et al. *Cancer Management: A Multidisciplinary Approach*. Third Edition, Melville, N.Y.: PRR Inc., 1999.

G. Richard Lee, ed., et al. *Wintrobe's Clinical Hematology*. Tenth Edition, 2 Vols. Baltimore: Williams & Wilkins, 1998.

Martin D. Abeloff, ed., et al. *Clinical Oncology*. New York: Churchill Livingstone, Inc., 1995.

Raymond E. Lenhard, Jr., Robert T. Osteen, and Ted Gansler, eds. *Clinical Oncology*. Atlanta: The American Cancer Society Inc., 2001.

Robert C. Bast, Jr., ed., et al. *Cancer Medicine*. Fifth Edition, Hamilton, Ontario: B.C. Decker, Inc., 2000.

Phillip A. Pizzo and David G. Poplack. *Principles and Practice of Pediatric Oncology*. Third Edition, Philadelphia: Lippincott-Raven, 1997.

Anthony S. Fauci, ed., et al. *Principles of Internal Medicine*. Fourteenth Edition, New York: McGraw Hill, 1998:334-364, 493-747.

Arnold T. Sigler and William H. Zinkham. "Anemia." *Sports and Exercise for Children with Chronic Health Conditions*. Barry Goldberg, ed. Champaign: Human Kinetics, 1995:290-299.

Margot S. Kruskal. "The Perils of Platelet Transfusions." *The New England Journal of Medicine*, 337(26) 25 December 1997:1914-1915.

James Abbruzzese, et al. "Unknown Primary Carcinoma: Natural History and Prognostic Factors in 657 Consecutive Patients." *Journal of Clinical Oncology*, 12(6) June 1994:1272-1280.

Samy El-Sayed and Norma Nelson. "Adjuvant and Adjunctive Chemotherapy in the Management of Squamous Cell Carcinoma of the Head and Neck Region: A Meta-Analysis of Prospective and Randomized Trials." *Journal of Clinical Oncology*, 14(3) March 1996:838-847.

John M. Kirkwood, et al. "Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684." *Journal of Clinical Oncology*, 14(1) January 1996:7-17.

Lauren Abrey, Lisa DeAngelis, and Joachim Yahalom. "Long-Term Survival in Primary CNS Lymphoma." *Journal of Clinical Oncology*, 16(3) March 1998:859-863.

Marianne J. Hejermstad, et al. "Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study." *Journal of Clinical Oncology*, 17(2) February 1999:706-718.

Katherine K. Matthay. "Stage 4S Neuroblastoma: What Makes It Special?" *Journal of Clinical Oncology*, 16(6) June 1998:2003-2006.

W. Mendenhall, et al. "Is Radiation Therapy a Preferred Alternative to Surgery for Squamous Cell Carcinoma of the Base of Tongue?" *Journal of Clinical Oncology*, 18(1) January 2000:35-42.

Saul A. Rosenberg. "Classification of Lymphoid Neoplasms." *Blood*, 84(5) 1 September 1994:1359-1360.

Nancy Lee Harris, et al. "A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group." *Blood*, 84(5) 1 September 1994:1361-1392.

Hannes Wandt, et al. "Safety and Cost Effectiveness of a 10 x 10<sup>9</sup>/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 x 10<sup>9</sup>/L Trigger: a Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia." *Blood*, 91(10) 15 May 1998:3601-3606.

Stefan Faderl, et al. "Chronic Myelogenous Leukemia: Biology and Therapy." *Annals of Internal Medicine*, 131(3) 3 August 1999:207-219.

David P. Ryan, Carolyn C. Compton, and Robert J. Mayer. "Carcinoma of the Anal Canal." *The New England Journal of Medicine*, 342(11) 16 March 2000:792-799.

Mario A. Eissenberger, et al. "Bilateral Orchiectomy With Or Without Flutamide For Metastatic Prostate Cancer." *The New England Journal of Medicine*, 339(15) 8 October 1998:1036-1042.

Scott T. Miller, et al. "Prediction of Adverse Outcomes in Children with Sickle Cell Disease." *The New England Journal of Medicine*, 342(2) 13 January 2000:83-89.

C. P. Karakousis. "Surgical Treatment of Malignant Melanoma." *Surgical Clinics of North America*, 76(6) December 1996:1299-1312.

Martin H. Steinberg. "Sickle Cell Disease: Pathophysiology, Diagnosis, and Treatment." *Federal Practitioner*, December 1998:22-47.

Michael D. Prados, Mitchell S. Berger, and Charles B. Wilson. "Primary Central Nervous System Tumors: Advances in Knowledge and Treatment." *CA—A Cancer Journal for Clinicians*, 48(6) November/December 1998:331-360.

D. H. Kraus, et al. "Surgical management of squamous cell carcinoma of the base of the tongue." *American Journal of Surgery*, 166(4) October 1993:384-388.

David M. Brizel, et al. "Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer." *New England Journal of Medicine*, 338(25) 18 June 1998:1798-1804.

H. J. Lee, et al. "Long-term regional control after radiation therapy and neck dissection for base of tongue carcinoma." *International Journal of Radiation Oncology, Biology and Physics*, 38(5) 15 July 1997: 995-1000.

D. P. Derman, et al. "Adjuvant Chemotherapy (CMF) For Stage III Breast Cancer: A Randomized Trial." *International Journal of Radiation Oncology, Biology and Physics*, 17(2) August 1989:257-261.

Karen J. Halverson, et al. "Survival Following Locoregional Recurrence Of Breast Cancer: Univariate And Multivariate Analysis." *International Journal of Radiation Oncology, Biology and Physics*, 23(2) 1992:285-291.

Benjamin Corn, et al. "Endometrial Cancer With Para-Aortic Adenopathy: Patterns Of Failure And Opportunities For Cure." *International Journal of Radiation Oncology, Biology and Physics*, 24(2) 1992:223-227.

L. B. Harrison, et al. "Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue." *Head & Neck*, 19(3) May 1997:169-175.

G. J. Moore, J. T. Parsons, and W. M. Mendenhall. "Quality of life outcomes after primary radiotherapy for squamous cell carcinoma of the base of tongue."

*International Journal of Radiation Oncology, Biology and Physics*, 36(2) 1 September 1996:351–354.

M. Machtay, *et al.* "Combined surgery and postoperative radiotherapy for carcinoma of the base of the tongue: analysis of treatment outcome and prognostic value of margin status." *Head & Neck*, 19(6) September 1997:494–499.

Arlene A. Forastiere, *et al.* "NCCN Practice Guidelines for Head and Neck Cancer." *Oncology*, 14(11A) November 2000:163–194.

William H. Zinkham, Alexander J. Seidler, and Thomas S. Kickler. "Variable degrees of suppression of hemoglobin S synthesis in subjects with hemoglobin SS disease on a long-term transfusion regimen." *Journal of Pediatrics*, 124 February 1994:215–219.

Clifton F. Mountain. "Revision in the International System for Staging Lung Cancer." *Chest*, 111(6) June 1997:1710–1717.

Clifton F. Mountain and Carolyn M. Dresler. "Regional Lymph Node Classification for Lung Cancer Staging." *Chest*, 111(6) June 1997:1718–1723.

James R. Jett. "What's New in Staging of Lung Cancer?" *Chest*, 111(6) June 1997:1486–1487.

James E. Krook, *et al.* "A Prospective, Randomized Evaluation of Intensive-Course 5-Fluorouracil Plus Doxorubicin as Surgical Adjuvant Chemotherapy for Resected Gastric Cancer." *Cancer*, 67(10) 15 May 1991:2454–2458.

Aman U. Busdar, *et al.* "Clinical Course of Patients With Breast Cancer With Ten or More Positive Nodes Who Were Treated With Doxorubicin-Containing Adjuvant Therapy." *Cancer*, 69(2) 15 January 1992:448–452.

William J. Hoskins. "Surgical Staging and Cytoreductive Surgery of Epithelial Ovarian Cancer." *Cancer Supplement*, 71(4) 15 February 1993:1534–1540.

Carlos Perez, *et al.* "Management of Locally Advanced Carcinoma of the Breast." *Cancer Supplement*, 74(1) 1 July 1994:466–476.

Stephen C. Rubin, *et al.* "Prognostic Factors for Recurrence following Negative Second-Look Laparotomy in Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy<sup>1,2</sup>." *Gynecologic Oncology*, 42 3 January 1991:137–141.

Naoto T. Ueno, *et al.* "Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center." *Cancer Chemotherapy and Pharmacology*, 40 1997:321–329.

Michael Moore, *et al.* "Inflammatory Breast Cancer." *Archives of Surgery*, 126 March 1991:304–306.

Aman U. Buzdar, *et al.* "Ten-Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer." *American Journal of Clinical Oncology*, 12(2) 1989:123–128.

B. A. Leone, *et al.* "Stage IV Breast Cancer: Clinical Course and Survival of Patients with Osseous Versus Extraosseous Metastases at Initial Diagnosis." *American Journal of Clinical Oncology*, 11(6) 1988:618–622.

Michael M. Sherry, *et al.* "Metastatic Breast Cancer Confined to the Skeletal System." *American Journal of Medicine*, 81 September 1986:381–386.

Per-Uno Malmstrom, *et al.* "Five-Year Followup Of A Prospective Trial Of Radical Cystectomy And Neoadjuvant Chemotherapy: Nordic Cystectomy Trial I." *The Journal of Urology*, 55 June 1996:1903–1906.

Mario A. Eisenberger, *et al.* "Prognostic Factors in Stage D<sub>2</sub> Prostate Cancer: Important Implications for Future Trials: Results of a Cooperative Intergroup Study (INT. 0036)." *Seminars in Oncology*, 21(5) October 1994:613–619.

Charles M. Balch, *et al.* "A Multifactorial Analysis of Melanoma." *Annals of Surgery*, 193(3) March 1981:377–388.

"A Genetic Overview of Thalassemia" available at <<http://www.thalassemia.com/genetics>>.

"Psycho-social Aspects" available at <<http://www.thalassemia.com/psych>>.

"Thalassemia" available at <<http://sickle.bwh.harvard.edu/thalover.html>>.

"Medical Management" available at <<http://www.thalassemia.com/medical/definition.shtml>>.

"Frequently Asked Questions" available at <<http://www.thalassemia.com/faq>>.

"Sickle Cell Anemia" available at <<http://www.healthanswers.com/database/ami/converted/000527.html>>.

"Sickle Cell Anemia" available at <<http://www.emory.edu/PEDS/SICKLE/sicklept.htm>>.

"Anemia" available at <<http://www.mayohhealth.org/mayo/9511/htm/anemia.htm>>.

These references are included in the rulemaking record for these proposed rules and are available for inspection by interested persons by making arrangements with the contact person shown above.

Dated: April 4, 2002.

**Jo Anne B. Barnhart,**

*Commissioner of Social Security.*

[FR Doc. 02–9468 Filed 4–17–02; 8:45 am]

**BILLING CODE 4191–02–P**

## DEPARTMENT OF LABOR

### Mine Safety and Health Administration

#### 30 CFR Parts 58 and 72

**RIN 1219–AB24**

#### Measuring and Controlling Asbestos Exposure

**AGENCY:** Mine Safety and Health Administration, Labor.

**ACTION:** Notice of change to public meetings.

**SUMMARY:** The Mine Safety and Health Administration is announcing a change in the date of one of our public meetings concerning the measurement and control of miners' exposure to asbestos. These meetings were announced March 29, 2002 in the **Federal Register** (67 FR 15134) in conjunction with an Advanced Notice of Proposed Rulemaking and Close of Record Notice. We are changing the date of the Charlottesville, Virginia meeting and adding a seventh public meeting in Phoenix, Arizona.

**DATES:** The public meeting in Phoenix, Arizona will be held on June 5, 2002. The public meeting in Charlottesville, Virginia will be held on June 20, 2002. The dates and locations of the other public meetings are listed in the Public Meetings section below under **SUPPLEMENTARY INFORMATION** for the convenience of the public.

You do not have to submit a written request to speak. There will be a sign-up sheet at each of the meeting locations. Speakers will speak in the order that they sign in. Speakers may also present information to the MSHA panel for inclusion in the rulemaking record.

**ADDRESSES:** The public meeting in Phoenix, Arizona will be held at the Hampton Inn Phoenix Midtown, 160 West Catalina Drive, Phoenix, AZ 85013 ((602) 200–0990). The public meeting in Charlottesville, Virginia will be held at the Holiday Inn, 1901 Emmet Street, Charlottesville, VA 22901 ((434) 977–7700). The public meeting dates and locations of the other five public meetings are listed in the Public Meetings section below under **SUPPLEMENTARY INFORMATION** for the convenience of the public.

**FOR FURTHER INFORMATION CONTACT:** Marvin W. Nichols, Jr., Director; Office of Standards, Regulations, and Variances; MSHA, 4015 Wilson Boulevard, Arlington, Virginia 22203–1984. Mr. Nichols can be reached at [nichols-marvin@msha.gov](mailto:nichols-marvin@msha.gov) (E-mail), (703) 235–1910 (Voice), or 703–235–5551 (Fax).

#### SUPPLEMENTARY INFORMATION:

##### I. Public Meetings

The public meetings will be held on the following dates and at these locations:

Date	Location	Phone
May 2nd .....	Ramada Inn, 164 Fort Couch Road, Pittsburgh, PA 15241 .....	(412) 833–5300.
May 14th .....	Days Inn, 4212 W Sunset Blvd, Spokane, WA 99224 .....	(509) 747–2021.
May 16th .....	Hampton Inn & Suites, 800 Mason Street, Vacaville, CA 95687 .....	(707) 469–6200.